MX2021009777A - Formulaciones inyectables de fenol y metodos de su uso. - Google Patents

Formulaciones inyectables de fenol y metodos de su uso.

Info

Publication number
MX2021009777A
MX2021009777A MX2021009777A MX2021009777A MX2021009777A MX 2021009777 A MX2021009777 A MX 2021009777A MX 2021009777 A MX2021009777 A MX 2021009777A MX 2021009777 A MX2021009777 A MX 2021009777A MX 2021009777 A MX2021009777 A MX 2021009777A
Authority
MX
Mexico
Prior art keywords
phenol
injectable
methods
cyclodextrin
formulations
Prior art date
Application number
MX2021009777A
Other languages
English (en)
Spanish (es)
Inventor
David Penake
Leonard O''MAHONY
Sharon Hamm
John Devane
Imran; Ahmed
Original Assignee
Saol Int Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saol Int Development Ltd filed Critical Saol Int Development Ltd
Publication of MX2021009777A publication Critical patent/MX2021009777A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/347Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/738Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08Cellulose derivatives
    • C08L1/26Cellulose ethers
    • C08L1/28Alkyl ethers
    • C08L1/286Alkyl ethers substituted with acid radicals, e.g. carboxymethyl cellulose [CMC]
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16Cyclodextrin; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
MX2021009777A 2019-02-15 2020-01-29 Formulaciones inyectables de fenol y metodos de su uso. MX2021009777A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806188P 2019-02-15 2019-02-15
PCT/US2020/015690 WO2020167476A1 (en) 2019-02-15 2020-01-29 Injectable phenol formulations and methods of their use

Publications (1)

Publication Number Publication Date
MX2021009777A true MX2021009777A (es) 2021-12-15

Family

ID=72042651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009777A MX2021009777A (es) 2019-02-15 2020-01-29 Formulaciones inyectables de fenol y metodos de su uso.

Country Status (6)

Country Link
US (3) US10959962B2 (https=)
EP (1) EP3923916A4 (https=)
JP (1) JP7455852B2 (https=)
CA (1) CA3129648A1 (https=)
MX (1) MX2021009777A (https=)
WO (1) WO2020167476A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112691091A (zh) * 2021-01-09 2021-04-23 胡宝贤 低浓度石炭酸的新应用
US20230190660A1 (en) * 2021-12-03 2023-06-22 Path Encapsulated pharmaceutical compositions, related methods of making, and related methods of treatment
WO2025235121A1 (en) * 2024-05-07 2025-11-13 Teclison, Inc. Tirapazamine compositions and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59152320A (ja) * 1983-02-17 1984-08-31 Takeda Chem Ind Ltd 水性製剤
JPH0625056B2 (ja) 1989-06-01 1994-04-06 大幸薬品株式会社 鎮痙剤
WO2002089849A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
JP4150772B2 (ja) * 2001-09-14 2008-09-17 独立行政法人産業技術総合研究所 シクロデキストリンを含有するフェノール重合物
JP2005538983A (ja) 2002-07-19 2005-12-22 メステックス アクチエンゲゼルシャフト 関節痛の治療のための薬剤を製造するための神経毒性物質の使用および同薬剤を適用する方法
LT1713504T (lt) * 2004-01-30 2017-09-11 Zoetis Services Llc Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms
US20120190750A1 (en) * 2011-01-24 2012-07-26 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable ready to use injectable paracetamol formulation
ES2784629T3 (es) * 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
US9295512B2 (en) 2013-03-15 2016-03-29 Myoscience, Inc. Methods and devices for pain management
JP6238190B2 (ja) * 2013-07-04 2017-11-29 公立大学法人大阪市立大学 コラーゲン産生促進用、エラスチン産生促進用および/またはケラチノサイト遊走促進用組成物
EP3024472A4 (en) 2013-07-22 2017-06-28 Kineta One, LLC Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
CN103602325B (zh) * 2013-11-18 2016-08-03 中国石油化工股份有限公司 一种延缓交联凝胶调剖剂及其制备方法
US20170209389A1 (en) 2014-07-23 2017-07-27 Landy Toth Precision chemical ablation and treatment of tissues
EP4059522A1 (en) * 2015-02-06 2022-09-21 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
US9855317B2 (en) 2015-04-27 2018-01-02 Reflex Medical, Inc. Systems and methods for sympathetic cardiopulmonary neuromodulation
WO2017180708A1 (en) * 2016-04-12 2017-10-19 Cell and Molecular Tissue Engineering, LLC Systems, methods and products for minimizing tissue reactions and tissue injury at an infusion site

Also Published As

Publication number Publication date
US20210145766A1 (en) 2021-05-20
EP3923916A4 (en) 2022-12-21
US10959962B2 (en) 2021-03-30
US11083695B2 (en) 2021-08-10
JP7455852B2 (ja) 2024-03-26
EP3923916A1 (en) 2021-12-22
WO2020167476A1 (en) 2020-08-20
US20210145767A1 (en) 2021-05-20
JP2022520779A (ja) 2022-04-01
US20200261377A1 (en) 2020-08-20
US11083694B2 (en) 2021-08-10
CA3129648A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
MX2024007720A (es) Lipidos para la administracion de agentes activos en nanoparticulas lipidicas.
MX2021009777A (es) Formulaciones inyectables de fenol y metodos de su uso.
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
AR029462A1 (es) Derivados del acido picolinico, procedimiento para prepararlos y composiciones formuladas con dichos derivados como agente activo, procedimientos preventivos o curativos contra hongos fitopatogenos, metodos preventivos o de tratamiento de la madera para la construccion utilizando dichos compuestos y
MX2020010502A (es) Agentes farmacológicos para el tratamiento de enfermedades oculares.
HUP0105173A2 (hu) Adagolási módszer és készítmény sürgősségi fogamzásgátlásra
JP2017538767A (ja) 毛包虫症治療のためのイソオキサゾリン化合物の使用
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
WO2021022058A3 (en) Antiarrhythmic formulation
MX2024002409A (es) Terapias contra el cancer.
ATE533509T1 (de) Herzverlangsamender arzneistoff mit beta-blockern mit kurzzeitwirkung als wirkstoff
MX2025002126A (es) Tratamientos con dosis unitarias fijas del anticuerpo actrii
MY195178A (en) Composition for Treating Joint Disease and Kit Containing Same
AR045263A1 (es) Metodo, kit y composicion farmaceutica para tratar infecciones virales
PL374083A1 (en) Sgk and nedd used as diagnostic and therapeutic targets
MX9304197A (es) Nuevo uso de dimero de lisozina y composiciones que lo contienen.
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
AU2020299145A8 (en) Compositions and methods for treating eye diseases
WO2021102161A8 (en) Methods for treating inflammatory bowel disease
WO2024020361A3 (en) Inhalable serotonin receptor agonist formulations
BR112023016459A2 (pt) Métodos terapêuticos
AU2006324315A1 (en) Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine
NZ766141A (en) Isoxazoline parasiticide formulations and methods for treating blepharitis